Emergent BioSolutions announced that it has secured a $54 million contract to deliver CNJ‑016, a vaccinia immune globulin intravenous product, to the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR). In addition, the company received new incremental orders worth $6.6 million for its ACAM2000 smallpox vaccine from an international government partner, bringing the total value of the new contracts to $60.6 million.
The contracts arrive at a time when Emergent’s financial performance has been volatile. In Q4 2024 the company reported $194.7 million in revenue and a $31.3 million net loss, while Q1 2025 revenue rose to $222.2 million with a $68 million net income. The MCM Products segment, which includes CNJ‑016 and ACAM2000, grew 112% in Q1 2025 versus Q1 2024, underscoring the strategic importance of these new government contracts. The company also has a multi‑year agreement with Canada valued up to $140 million CAD, with $35 million CAD expected in 2026, further highlighting its role in global biodefense supply chains.
"We are pleased to support both the U.S. government and a longstanding international partner with critical smallpox medical countermeasures that directly align with their national security and public health preparedness efforts," said Paul Williams, Senior Vice President, Head of Products Business, Global Government & Public Affairs. "Our strong track record of developing, manufacturing and supplying biodefense products to international governments reinforces the strength of our partnerships, particularly in light of the growing risk of biological threats globally." CEO Joe Papa added that the company has been executing a multi‑year strategic plan to stabilize operations and drive profitability, noting that the new contracts provide a reliable revenue base as the company focuses on its core MCM and NARCAN nasal spray businesses.
The $60.6 million in new contracts is a tailwind for Emergent’s MCM segment, offering a predictable revenue stream that offsets headwinds in its commercial product lines. The company’s adjusted gross margin expanded to 58% in Q1 2025 from 40% in the prior year, and its adjusted EBITDA margin nearly doubled to 28% in 2025 from 18% in 2024, indicating that the MCM business is contributing to margin improvement. By securing these contracts, Emergent strengthens its position in the U.S. strategic national stockpile and demonstrates its ability to win recurring business with government agencies.
The announcement was met with a modest positive market reaction, though investors remained focused on the company’s broader financial outlook. The company’s 2026 revenue guidance of $720‑$760 million—significantly lower than earlier expectations—has been a source of concern, but the new contracts provide a degree of stability amid a challenging revenue environment.
The contracts reinforce Emergent’s strategic focus on medical countermeasures and highlight the company’s resilience in securing government funding. While the 2026 guidance signals ongoing revenue pressure, the steady inflow from ASPR and the international partner offers a buffer that may help the company navigate competitive pressures in its commercial segments and continue to pursue its turnaround plan.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.